Leukemia rapid test Xpert®

for genetic disordersfor BCR-ABL mutationsfor BCR-ABL

Sensitive and quantitative monitoring of BCR-ABL mRNA in patients with chronic myelogenous leukemia (CML) The Need Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias.1 Successful treatments with Tyrosine Kinase Inhibitors (TKIs) have greatly improved the outcome for most patients, significantly decreasing annual mortality and increasing prevalence.2,3 International guidelines recommend monitoring BCR::ABL1 transcript levels on an international reporting scale (IS) by quantitative RT-PCR (qPCR) at regular intervals to assess the efficacy and safety of the treatment.4-7 The Solution The Xpert BCR-ABL Ultra is a quantitative test for BCR::ABL major breakpoint (p210) transcripts that provides highly sensitive and on-demand molecular results, reporting on both the International Scale (IS) and Molecular Response (MR) formats.11 Accurate, on-demand process with results aligned to the IS in a one-page report in approximately 3 hours.11 The Impact Delivers same-day results to support informed and timely clinical decisions, aiding in improved patient care.8,9 Flexibility and simplicity of an optimized and on-demand testing workflow improves overall cost and efficiency.10 Eliminates the need for standard curve and replicate testing freeing up technician time for other lab services.11